Post by PharmaShots

The US FDA approves MSD’s Keytruda and Keytruda Qlex plus Gilead Sciences' Trodelvy as the first PD-1 inhibitor/Trop-2 ADC combination for first-line PD-L1+ advanced triple-negative breast cancer Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #merck #gilead #trodelvy #ascent04 #keynoted19 #tnbc #keytruda #usfda #approval #regulatory #oncology #breastcancer https://lnkd.in/gsSdmYCU